Investor Relations

Investor Relations

Corporate Profile

About Shionogi Pharma, Inc.
Shionogi Pharma, Inc. (formerly Sciele Pharma, Inc.), is a US-based group company of Shionogi & Co., Ltd, based in Atlanta, Georgia specializing in sales, marketing and development of branded prescription products focused on Cardiovascular/Diabetes, Women's Health and Pediatrics. The Company's Cardiovascular/Diabetes products treat patients with high cholesterol, hypertension, high triglycerides, unstable angina and type 2 diabetes; its Women's Health products are designed to improve the health and well-being of women and mothers and their babies; and its Pediatrics products treat allergies, asthma, head lice infestations, and attention deficit/hyperactivity disorder (ADHD).

About Shionogi & Co., Ltd.
Shionogi & Co., Ltd., headquartered in Osaka, Japan, is a major research-driven pharmaceutical company dedicated to placing the highest value on patients. Shionogi's Research and Development currently targets three therapeutic areas: Infectious Diseases, Pain, and Metabolic Syndrome. The Company has provided such innovative medicines as Crestor and Doripenem, which have been successfully delivered to millions of people who need them. In addition, Shionogi is engaged in some new research areas such as allergy and cancer. Contributing to the health of patients around the world through development in these therapeutic areas is Shionogi's primary goal. For more details, please visit www.shionogi.co.jp.

Tokyo Stock Exchange (4507)
Featured Reports and Presentations
Download Documentation Title: Third Medium-Term Business Plan
Download Documentation Title: 2009 Shionogi Annual Report

Shionogi & Co., LTD. News Releases

Sciele Pharma Recent NewsMore >>
DateTitle 
06/01/10PIVOTAL DATA FOR THE INVESTIGATIONAL TREATMENT PSD502 FOR PRIMARY PREMATURE EJACULATION IN THE UNITED STATES TO BE PRESENTED AT MAJOR MEDICAL MEETINGPrinter Friendly Version
05/26/10Five Clinical Presentations Highlight Shionogi Pharma, Inc.'s PSD502, an Investigational Treatment For Primary Premature Ejaculation Printer Friendly Version
04/01/10Shionogi’s Nitrolingual® Pumpspray is Available for Angina Pectoris PatientsPrinter Friendly Version
03/16/10Shionogi's Third Medium-Term Business PlanPrinter Friendly Version